entresto 200 mg
novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy
entresto 50 mg
novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entresto is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entresto has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy
entresto 50 mg
novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy
entresto 50 mg
novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy
entresto 100mg film-coated tablet (eq. to sacubitril 48.6 mg and valsartan 51.4 mg sodium salt complex)
novartis healthcare philippines, inc.; distributor: novartis healthcare philippines, inc. - sacubitril-valsartan - film-coated tablet (eq. to sacubitril 48.6 mg and valsartan 51.4 mg sodium salt complex) - 100mg
entresto 50mg film-coated tablet (eq. to sacubitril 24.3 mg and valsartan 25.7 mg sodium salt complex)
novartis healthcare philippines, inc.; distributor: novartis healthcare philippines, inc. - sacubitril-valsartan - film-coated tablet (eq. to sacubitril 24.3 mg and valsartan 25.7 mg sodium salt complex) - 50mg
entresto 200mg film-coated tablet (eq. to sacubitril 97.2 mg and valsartan 102.8 mg sodium salt complex)
novartis healthcare philippines, inc.; distributor: novartis healthcare philippines, inc. - sacubitril-valsartan - film-coated tablet (eq. to sacubitril 97.2 mg and valsartan 102.8 mg sodium salt complex) - 200mg
vymada 50mg (eq. to sacubitril 24.3mg and valsartan 25.7mg sodium salt complex) film-coated tablet
novartis healthcare philippines, inc.; distributor: novartis healthcare philippines, inc. - sacubitril-valsartan - film-coated tablet - 50mg (eq. to sacubitril 24.3mg and valsartan 25.7mg sodium salt complex)
sabsar tablet 49mg + 51mg coated tablet
sacubitril 49mg + valsartan 51mg - coated tablet - sacubitril 49mg + valsartan 51mg - valsartan and sacubitril
sabsar tablet 97mg + 103mg coated tablet
sacubitril 97mg + valsartan 103mg - coated tablet - sacubitril 97mg + valsartan 103mg - valsartan and sacubitril